Clinical Trial Update: Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune Encephalitis [Phase 3]

View source ↗

Summary

A Phase 3 trial is evaluating the safety and efficacy of combining B cell–depleting therapy with Daratumumab for anti-NMDA receptor encephalitis. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anti-nmda Receptor Encephalitis

Drugs mentioned

• B cell depleting therapy (unspecified)
• Daratumumab (daratumumab)

Snippet

Sponsor: The First People's Hospital of Changzhou | Conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis | Phase 3 | Status: RECRUITING